Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma

Next Previous
X
Search
Trial Profile

A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary) ; Fluticasone propionate
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 14 Nov 2022 Results of post hoc analysis examined data from the IA05 (NCT00079937) and PROSPERO (NCT01922037), presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
    • 08 Nov 2021 Results of post-hoc sub-group analysis was presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
    • 25 Feb 2019 Results of post-hoc analysis assessing blood eosinophil levels data from three phase III studies including this study at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top